Chlamydia pneumoniae and atherosclerosis

Robert J. Belland, Scot P. Ouellette, Jens Gieffers, Gerald I. Byrne

Research output: Contribution to journalReview article

125 Citations (Scopus)

Abstract

Exposure to Chlamydia pneumoniae is extremely common, and respiratory infections occur repeatedly among most people. Strong associations exist between C. pneumoniae infection and atherosclerosis as demonstrated by: (i) sero-epidemiological studies showing that patients with cardiovascular disease have higher titres of anti-C. pneumoniae antibodies compared with control patients; (ii) detection of the organism within atherosclerotic lesions, but not in adjacent normal tissue by immunohistochemistry, polymerase chain reaction and electron microscopy and by culturing the organism from lesions; and (iii) showing that C. pneumoniae can either initiate lesion development or cause exacerbation of lesions in rabbit and mouse animal models respectively. The association of this organism with atherosclerosis has also provided sufficient impetus to conduct a variety of human secondary prevention antibiotic treatment trials. The results of these studies have been mixed and, thus far, no clear long-lasting benefit has emerged from these types of investigations. Studies of C. pneumoniae pathogenesis have shown that the organism can infect many cell types associated with both respiratory and cardiovascular sites, including lung epithelium and resident alveolar macrophages, circulating monocytes, arterial smooth muscle cells and vascular endothellum. Infected cells have been shown to exhibit characteristics associated with the development of cardiovascular disease (e.g. secretion of proinflammatory cytokines and procoagulants by infected endothelial cells and foam cell formation by infected macrophages). More detailed analysis of C. pneumoniae pathogenesis has been aided by the availability of genomic sequence information. Genomic and proteomic analyses of C. pneumoniae infections in relevant cell types will help to define the pathogenic potential of the organism in both respiratory and cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)117-127
Number of pages11
JournalCellular Microbiology
Volume6
Issue number2
DOIs
StatePublished - Feb 1 2004

Fingerprint

Chlamydophila pneumoniae
Atherosclerosis
Chlamydia Infections
Cardiovascular Diseases
Foam Cells
Alveolar Macrophages
Secondary Prevention
Respiratory Tract Infections
Proteomics
Smooth Muscle Myocytes
Blood Vessels
Epidemiologic Studies
Monocytes
Electron Microscopy
Epithelium
Endothelial Cells
Animal Models
Immunohistochemistry
Macrophages
Cytokines

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Virology

Cite this

Chlamydia pneumoniae and atherosclerosis. / Belland, Robert J.; Ouellette, Scot P.; Gieffers, Jens; Byrne, Gerald I.

In: Cellular Microbiology, Vol. 6, No. 2, 01.02.2004, p. 117-127.

Research output: Contribution to journalReview article

Belland, Robert J. ; Ouellette, Scot P. ; Gieffers, Jens ; Byrne, Gerald I. / Chlamydia pneumoniae and atherosclerosis. In: Cellular Microbiology. 2004 ; Vol. 6, No. 2. pp. 117-127.
@article{83e41aef8ab34dfd997650a888f8007c,
title = "Chlamydia pneumoniae and atherosclerosis",
abstract = "Exposure to Chlamydia pneumoniae is extremely common, and respiratory infections occur repeatedly among most people. Strong associations exist between C. pneumoniae infection and atherosclerosis as demonstrated by: (i) sero-epidemiological studies showing that patients with cardiovascular disease have higher titres of anti-C. pneumoniae antibodies compared with control patients; (ii) detection of the organism within atherosclerotic lesions, but not in adjacent normal tissue by immunohistochemistry, polymerase chain reaction and electron microscopy and by culturing the organism from lesions; and (iii) showing that C. pneumoniae can either initiate lesion development or cause exacerbation of lesions in rabbit and mouse animal models respectively. The association of this organism with atherosclerosis has also provided sufficient impetus to conduct a variety of human secondary prevention antibiotic treatment trials. The results of these studies have been mixed and, thus far, no clear long-lasting benefit has emerged from these types of investigations. Studies of C. pneumoniae pathogenesis have shown that the organism can infect many cell types associated with both respiratory and cardiovascular sites, including lung epithelium and resident alveolar macrophages, circulating monocytes, arterial smooth muscle cells and vascular endothellum. Infected cells have been shown to exhibit characteristics associated with the development of cardiovascular disease (e.g. secretion of proinflammatory cytokines and procoagulants by infected endothelial cells and foam cell formation by infected macrophages). More detailed analysis of C. pneumoniae pathogenesis has been aided by the availability of genomic sequence information. Genomic and proteomic analyses of C. pneumoniae infections in relevant cell types will help to define the pathogenic potential of the organism in both respiratory and cardiovascular disease.",
author = "Belland, {Robert J.} and Ouellette, {Scot P.} and Jens Gieffers and Byrne, {Gerald I.}",
year = "2004",
month = "2",
day = "1",
doi = "10.1046/j.1462-5822.2003.00352.x",
language = "English (US)",
volume = "6",
pages = "117--127",
journal = "Cellular Microbiology",
issn = "1462-5814",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Chlamydia pneumoniae and atherosclerosis

AU - Belland, Robert J.

AU - Ouellette, Scot P.

AU - Gieffers, Jens

AU - Byrne, Gerald I.

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Exposure to Chlamydia pneumoniae is extremely common, and respiratory infections occur repeatedly among most people. Strong associations exist between C. pneumoniae infection and atherosclerosis as demonstrated by: (i) sero-epidemiological studies showing that patients with cardiovascular disease have higher titres of anti-C. pneumoniae antibodies compared with control patients; (ii) detection of the organism within atherosclerotic lesions, but not in adjacent normal tissue by immunohistochemistry, polymerase chain reaction and electron microscopy and by culturing the organism from lesions; and (iii) showing that C. pneumoniae can either initiate lesion development or cause exacerbation of lesions in rabbit and mouse animal models respectively. The association of this organism with atherosclerosis has also provided sufficient impetus to conduct a variety of human secondary prevention antibiotic treatment trials. The results of these studies have been mixed and, thus far, no clear long-lasting benefit has emerged from these types of investigations. Studies of C. pneumoniae pathogenesis have shown that the organism can infect many cell types associated with both respiratory and cardiovascular sites, including lung epithelium and resident alveolar macrophages, circulating monocytes, arterial smooth muscle cells and vascular endothellum. Infected cells have been shown to exhibit characteristics associated with the development of cardiovascular disease (e.g. secretion of proinflammatory cytokines and procoagulants by infected endothelial cells and foam cell formation by infected macrophages). More detailed analysis of C. pneumoniae pathogenesis has been aided by the availability of genomic sequence information. Genomic and proteomic analyses of C. pneumoniae infections in relevant cell types will help to define the pathogenic potential of the organism in both respiratory and cardiovascular disease.

AB - Exposure to Chlamydia pneumoniae is extremely common, and respiratory infections occur repeatedly among most people. Strong associations exist between C. pneumoniae infection and atherosclerosis as demonstrated by: (i) sero-epidemiological studies showing that patients with cardiovascular disease have higher titres of anti-C. pneumoniae antibodies compared with control patients; (ii) detection of the organism within atherosclerotic lesions, but not in adjacent normal tissue by immunohistochemistry, polymerase chain reaction and electron microscopy and by culturing the organism from lesions; and (iii) showing that C. pneumoniae can either initiate lesion development or cause exacerbation of lesions in rabbit and mouse animal models respectively. The association of this organism with atherosclerosis has also provided sufficient impetus to conduct a variety of human secondary prevention antibiotic treatment trials. The results of these studies have been mixed and, thus far, no clear long-lasting benefit has emerged from these types of investigations. Studies of C. pneumoniae pathogenesis have shown that the organism can infect many cell types associated with both respiratory and cardiovascular sites, including lung epithelium and resident alveolar macrophages, circulating monocytes, arterial smooth muscle cells and vascular endothellum. Infected cells have been shown to exhibit characteristics associated with the development of cardiovascular disease (e.g. secretion of proinflammatory cytokines and procoagulants by infected endothelial cells and foam cell formation by infected macrophages). More detailed analysis of C. pneumoniae pathogenesis has been aided by the availability of genomic sequence information. Genomic and proteomic analyses of C. pneumoniae infections in relevant cell types will help to define the pathogenic potential of the organism in both respiratory and cardiovascular disease.

UR - http://www.scopus.com/inward/record.url?scp=1642431985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642431985&partnerID=8YFLogxK

U2 - 10.1046/j.1462-5822.2003.00352.x

DO - 10.1046/j.1462-5822.2003.00352.x

M3 - Review article

C2 - 14706098

AN - SCOPUS:1642431985

VL - 6

SP - 117

EP - 127

JO - Cellular Microbiology

JF - Cellular Microbiology

SN - 1462-5814

IS - 2

ER -